KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Income from Continuing Operations: 2010-2024

Historic Income from Continuing Operations for TherapeuticsMD (TXMD) over the last 15 years, with Dec 2024 value amounting to -$2.3 million.

  • TherapeuticsMD's Income from Continuing Operations rose 108.82% to $50,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $42,000, marking a year-over-year increase of 101.05%. This contributed to the annual value of -$2.3 million for FY2024, which is 69.97% up from last year.
  • TherapeuticsMD's Income from Continuing Operations amounted to -$2.3 million in FY2024, which was up 69.97% from -$7.7 million recorded in FY2023.
  • In the past 5 years, TherapeuticsMD's Income from Continuing Operations registered a high of $1.1 million during FY2022, and its lowest value of -$183.5 million during FY2020.
  • In the last 3 years, TherapeuticsMD's Income from Continuing Operations had a median value of -$2.3 million in 2024 and averaged -$3.0 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first spiked by 101.35% in 2022, then slumped by 816.85% in 2023.
  • TherapeuticsMD's Income from Continuing Operations (Yearly) stood at -$183.5 million in 2020, then skyrocketed by 56.79% to -$79.3 million in 2021, then surged by 101.35% to $1.1 million in 2022, then slumped by 816.85% to -$7.7 million in 2023, then skyrocketed by 69.97% to -$2.3 million in 2024.